A5005655376- Dementia and Cognitive Impairment Research
- Health Systems, Economic Evaluations, Quality of Life
- Health, Medicine and Society
- Pharmaceutical Practices and Patient Outcomes
- Aging, Elder Care, and Social Issues
- Healthcare Systems and Practices
- Chronic Disease Management Strategies
- Nutrition and Health in Aging
- Frailty in Older Adults
- Alzheimer's disease research and treatments
- Cholinesterase and Neurodegenerative Diseases
- Geriatric Care and Nursing Homes
- Intergenerational Family Dynamics and Caregiving
- Health disparities and outcomes
- Intensive Care Unit Cognitive Disorders
- Influenza Virus Research Studies
- Mental Health Treatment and Access
- Disaster Response and Management
- Anesthesia and Sedative Agents
- Blood Pressure and Hypertension Studies
- Pharmaceutical Economics and Policy
- Posttraumatic Stress Disorder Research
- Pharmaceutical industry and healthcare
- Nutritional Studies and Diet
- Sleep and related disorders
Université Toulouse III - Paul Sabatier
2015-2024
Université de Toulouse
2014-2024
Centre Hospitalier Universitaire de Toulouse
2015-2024
Inserm
2015-2024
Centre de recherche en Epidémiologie et Santé des Populations
2022
Hôpital Rangueil
2021
Hôpital de La Grave
2021
Laboratoire Epidémiologie et Analyses en Santé Publique : Risques, Maladies Chroniques et Handicaps
2017-2020
Santé Publique France
2020
University of Pittsburgh
2015
The oldest-old (individuals over 90 years) are a fast-growing population. Understanding the perceptions of older people about very old age is first step towards developing optimal geriatric care for an aging This study aimed to explore potential shift from through exploration people's perception aging.Qualitative conducted individual interviews in homes people. We voluntarily chose include persons decade under and above years other factors than that could participate age. sampling was...
Slow gait speed (GS) predicts dementia, but this association might be mediated by body composition parameters like total fat mass (TFM) or lean (TLM). The aim of the study was to evaluate whether GS, TLM, and TFM were associated factors with an increased risk for subsequent dementia in community-dwelling older women.A case-control nested EPIDemiologie de l'OStéoporose cohort. GS (at usual pace more than 6 m), (assessed dual energy x-ray absorptiometry) measured at baseline. Cognitive...
Abstract Background Patients with Alzheimer's disease (AD), even in the presence of symptomatic relief from medical intervention, face a persistent worsening cognitive decline and performance activities daily living. Data regarding long‐term progression outside therapeutic trials are lacking. We examined effects standard care for AD patients on prognosis real‐life study over 4‐year period. Methods A total 686 mild‐moderate were enrolled 16 memory clinics (REseau sur la maladie d’ Alzheimer...
Abstract Background Preventive interventions for dementia are urgently needed and must be tested in randomised controlled trials (RCTs). Selection (volunteer) bias may limit efficacy, particularly testing multidomain also indicative of disparities intervention uptake real-world settings. We identified factors associated with participation adherence a 3-year RCT lifestyle and/or omega-3 supplementation prevention cognitive decline explored reasons (non-) participation. Methods Ancillary study...
The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) relation to geographical location over a 2-years period. One thousand three hundred and six from 11 countries were clustered into 3 regions (North, South, West) investigated biannual follow-up 2 years. Primary outcomes cognitive, functional behavioral measures. Caregiver burden, hospital admission nursing home also recorded. Participant cognitive function declined...
<i>Background:</i> Attrition, i.e. patient dropout, can threaten the validity of results in longitudinal studies. The aim this study was to identify and caregiver factors predictive attrition a cohort Alzheimer disease (AD) patients. <i>Methods:</i> 686 patients with mild moderate AD were included multicenter prospective REAL.FR study. Standardized gerontological evaluations carried out twice yearly. Factors associated assessed by survival analysis using Cox...
Antipsychotics are widely used for the treatment of behavioral and psychological symptoms dementia (BPSD). Concerns have been raised in literature over safety antipsychotics, with suggestions an increased risk mortality. The objective this study was to determine all-cause mortality associated antipsychotic use among Alzheimer’s disease (AD) patients. A new-user conducted a multicentric prospective cohort, composed 534 community-dwelling mild-to-moderate AD patients recruited 16 French memory...
Many patients develop psychiatric and behavioral disturbances in the course of Alzheimer's disease (AD). Among these disturbances, depressive symptoms are frequent affect nearly 40% patients. The natural history such AD, particular predictive factors, little known. We studied incidence risk factors for development first AD.
Comprehensive geriatric assessments of patients entering the severe stage Alzheimer's disease (AD) are scarce.Cross-sectional study 126 AD in longitudinal REAL.FR cohort. Patients who had a first MMSE score <10 during follow-up underwent cognitive, behavioral, nutritional and functional assessment. Support requirements were also evaluated.The best-preserved cognitive abilities social interaction response to own name, while praxis, orientation, memory language showed largest declines....
ABSTRACT Background: Psychotropic medication is widely prescribed in clinical practice for the management of behavioral and psychological symptoms dementia (BPSD) Alzheimer's disease (AD). However, there have been few pharmaco-epidemiological studies or conducted a natural setting on real use antidepressants AD. The aim this survey was to assess prevalence antidepressant AD identify factors associated with prescription. Methods: REAL.FR four-year, prospective, multi-center study. Baseline...
The aim of the present study was to assess association between anticholinergic (atropinic) burden and cognitive decline in older adults over course 3 years.We used data from Multidomain Alzheimer Preventive Trial (MAPT) participants aged ≥70 years at risk decline. Cognitive function assessed with a composite score [Mini-Mental State Examination (MMSE) orientation, Free Cued Selective Reminding Test, Category Naming Digit Symbol Substitution Test] 12, 24 36 months. Participants declining by...
Missing data are frequent in Alzheimer's disease (AD) trials due to the age of participants and nature disease. This can lead bias decreased statistical power. We assessed level causes missing a 2-year randomised trial an AD patient management program (PLASA study), conducted sensitivity analyses on primary endpoint (functional decline), using various methods for handling data: complete case, LOCF, Z-score longitudinal mixed effects model, multiple imputation. By 2 years, 32% 1131 subjects...